CY1113637T1 - Ενωση αμινο πυραζολης - Google Patents

Ενωση αμινο πυραζολης

Info

Publication number
CY1113637T1
CY1113637T1 CY20121101146T CY121101146T CY1113637T1 CY 1113637 T1 CY1113637 T1 CY 1113637T1 CY 20121101146 T CY20121101146 T CY 20121101146T CY 121101146 T CY121101146 T CY 121101146T CY 1113637 T1 CY1113637 T1 CY 1113637T1
Authority
CY
Cyprus
Prior art keywords
pyrazolis
union
amino
myeloblastoma
leukemias
Prior art date
Application number
CY20121101146T
Other languages
Greek (el)
English (en)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Liandong Ma
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113637(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113637T1 publication Critical patent/CY1113637T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20121101146T 2008-12-16 2012-11-27 Ενωση αμινο πυραζολης CY1113637T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
EP09795842A EP2379557B1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (1)

Publication Number Publication Date
CY1113637T1 true CY1113637T1 (el) 2016-06-22

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101146T CY1113637T1 (el) 2008-12-16 2012-11-27 Ενωση αμινο πυραζολης

Country Status (38)

Country Link
US (2) US20100286139A1 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
PH12013502530A1 (en) * 2011-06-15 2014-01-27 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
US11299494B2 (en) * 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Jnk活性化阻害剤
CA2467718C (en) 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR20070104936A (ko) 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
BRPI0613501A2 (pt) * 2005-07-01 2011-01-11 Irm Llc composto, composição farmacêutica e uso do mesmo
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
PE20070543A1 (es) * 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
CN101321759A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
MX2009012612A (es) 2007-05-23 2009-12-07 Pharmacopeia Llc Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
AU2009330503B2 (en) 2012-06-07
SI2379557T1 (sl) 2013-02-28
US20100152181A1 (en) 2010-06-17
EP2379557A1 (en) 2011-10-26
HN2011001697A (es) 2013-11-26
AR074240A1 (es) 2011-01-05
CO6331442A2 (es) 2011-10-20
PT2379557E (pt) 2013-01-14
MY158691A (en) 2016-10-31
PL2379557T3 (pl) 2013-03-29
EP2379557B1 (en) 2012-10-31
KR101300458B1 (ko) 2013-08-30
HRP20120918T1 (hr) 2012-12-31
WO2010074947A1 (en) 2010-07-01
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
PA8851101A1 (es) 2010-07-27
ZA201103942B (en) 2012-08-29
EA019554B1 (ru) 2014-04-30
HK1160109A1 (en) 2012-08-10
CR20110341A (es) 2011-07-13
MX2011006441A (es) 2011-07-19
DOP2011000190A (es) 2011-07-31
CL2011001445A1 (es) 2011-11-11
US7897600B2 (en) 2011-03-01
CN102232075B (zh) 2013-12-11
DK2379557T3 (da) 2012-12-17
CA2744714A1 (en) 2010-07-01
PE20110549A1 (es) 2011-08-04
ECSP11011132A (es) 2011-07-29
CN102232075A (zh) 2011-11-02
JP5509217B2 (ja) 2014-06-04
TN2011000292A1 (en) 2012-12-17
TWI440640B (zh) 2014-06-11
AU2009330503A1 (en) 2010-07-01
KR20110084993A (ko) 2011-07-26
SG172202A1 (en) 2011-07-28
ES2396617T3 (es) 2013-02-22
BRPI0923048A2 (pt) 2018-09-25
JO2833B1 (en) 2014-09-15
CA2744714C (en) 2013-06-25
US20100286139A1 (en) 2010-11-11
JP2012512158A (ja) 2012-05-31
TW201024301A (en) 2010-07-01
IL213065A0 (en) 2011-07-31
UA104743C2 (ru) 2014-03-11
NZ592641A (en) 2013-01-25
EA201170831A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
JO2833B1 (en) Amino pyrazole compound
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
EA201171367A1 (ru) Винилиндазолильные соединения
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
MX346924B (es) Compuestos de diarilhidantoina.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
CY1117722T1 (el) Βελτιωμενη αγωγη του πολλαπλου μυελωματος
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MA33973B1 (fr) Méthodes de traitement du cancer à l'aide d'antagonistes de notch
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
UY31432A1 (es) Compuestos de diarilhidantoina
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
CY1114023T1 (el) Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog
TNSN08401A1 (en) Methods of treating diagnosing or detecting cancer
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
MX2010004259A (es) Tratamientos antitumorales mejorados.
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
CR7276A (es) Terapia de combinacion para el tratamiento del cancer